Join us for a conversation between prof. Kirsten Gronbaek and her guest prof. Dominik Wolf, as they discuss targeting the immune system in MDS management. In light of accumulating evidence that inflammatory signals play a role throughout disease evolution in MDS patients, prof. Wolf elucidates the current insights and possible future therapeutic options.

He uses the example of targeting NLRP3/IL-1 axis in low-risk MDS to highlight the need of understanding the underlying cellular biology to translate that knowledge into clinical approaches. He also discusses the concept of possibly targeting both non-clonal and clonal compartments for better patient outcomes in the future.

Tune in, to hear about other future directions in treatment of MDS, such as recent developments in CAR T-cell approaches and about the central role that allo-transplantation is likely to keep in the treatment of high-risk MDS. You will also hear about the potential link between inflammation and fatigue, which is clinically highly relevant, but as yet an unsolved issue in MDS.  

Host: prof. Kirsten Gronbaek

Guest: prof. Dominik Wolf

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe